GHO Capital-backed RoslinCT to acquire Lykan Bioscience.

GHO Capital-backed RoslinCT, a cell and gene therapy contract development and manufacturing organisation, agreed to acquire Lykan Bioscience, a provider of outsourced clinical and commercial manufacturing services for pharmaceutical and biotechnology companies. WindRose Health Investors have reinvested in the new combined group. Financial terms were not disclosed. "This combination puts us in a strong position as a leading global CDMO in the process development and manufacturing of advanced cell therapies, and we look forward to working with our new colleagues at Lykan to fuel future growth and meet the increasing demand for innovative therapies," Peter Coleman, RoslinCT CEO.